Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.00M | $-35.53M | $-3.33 |
| 2024 | $0.00 | $-51.87M | $-4.89 |
| 2023 | $0.00 | $-109.23M | $-15.42 |
| 2022 | $0.00 | $-58.79M | $-6.93 |
| 2021 | $45.73M | $-56.68M | $-6.66 |
Social Signal Score
Earnings
Wed, Mar 3(in 7 months)
Consensus estimate $-0.17 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Apr 10$-0.81 vs $-0.18miss
- Mon, Dec 29$-0.18 vs $-0.18beat
- Thu, Aug 7$-0.18 vs $-0.18beat
- Wed, Apr 30$-0.22 vs $-0.53beat
- Wed, Feb 26$-0.22 vs $-0.53beat
Estimates and results for ANL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ANLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
View source ↗